Internal Medicine, Medical Oncology · El Paso, TX
NPI
1508863408
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1901 Grandview Ave
El Paso, TX, 79902
Phone (915) 544-6750
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
59,027 services
Medicare patients, 2024
373
Average age 75
Drug cost, 2024
$5.4M
1,552 prescriptions
Company payments, 2025
$7,299
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ines J Sanchez-Rivera was code J1453 (injection, fosaprepitant, 1 mg), 5,400 times for 17 patients. In total Ines J Sanchez-Rivera billed 59,027 services in 138 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-01-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 5,400 | 17 | $0.11 | $594 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,328 | 13 | $0.09 | $116 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 652 | 30 | $0.09 | $58.69 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 400 | 20 | $0.66 | $265 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 357 | 133 | $11.35 | $4,051 |
| 36415 Venipuncture Blood Collection | Office | 321 | 110 | $8.65 | $2,777 |
| 85025 Blood Count | Office | 290 | 109 | $7.43 | $2,154 |
| 80053 Clinical Chemistry | Office | 281 | 109 | $10.30 | $2,894 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 260 | 12 | $0.24 | $63.23 |
| 99213 Office E&M - Established | Office | 248 | 134 | $60.76 | $15K |
| 99214 Office E&M - Established | Office | 201 | 86 | $87.51 | $18K |
| 96375 Injection Administration | Office | 187 | 43 | $11.16 | $2,086 |
| 96413 Chemotherapy Administration | Office | 149 | 61 | $94.84 | $14K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 85 | 15 | $4.33 | $368 |
| G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 77 | 25 | $257.03 | $20K |
By year: 2022 $616K for 35,591 services; 2023 $693K for 37,225 services; 2024 $1.1M for 59,027 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 321 | 110 | $8.65 | $2,777 |
| 85025 Blood Count | 290 | 109 | $7.43 | $2,154 |
| 80053 Clinical Chemistry | 281 | 109 | $10.30 | $2,894 |
| 82378 Clinical Chemistry | 31 | 13 | $18.58 | $576 |
| 82728 Clinical Chemistry | 31 | 12 | $13.36 | $414 |
| 83540 Clinical Chemistry | 27 | 11 | $6.34 | $171 |
| 83550 Clinical Chemistry | 27 | 11 | $8.57 | $231 |
| 86300 Immunoassay | 17 | 12 | $20.39 | $347 |
Medicare prescription drug claims, 2024
In 2024, the drug Ines J Sanchez-Rivera prescribed most often to Medicare patients was Anastrozole, with 371 prescriptions and refills. In total Ines J Sanchez-Rivera wrote 1,552 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 371 | 847 | 103 | $4,592 |
| Gabapentin Generic | 73 | 104 | 19 | $809 |
| Kisqali Ribociclib Succinate | 63 | 63 | Under 11 | $1.2M |
| Dexamethasone Generic | 61 | 73 | 22 | $1,181 |
| Ibrance Palbociclib | 56 | 56 | Under 11 | $892K |
| Eliquis Apixaban | 51 | 64 | Under 11 | $36K |
| Inlyta Axitinib | 48 | 48 | Under 11 | $972K |
| Letrozole Generic | 46 | 110 | 12 | $838 |
| Acyclovir Generic | 42 | 48 | Under 11 | $306 |
| Exemestane Generic | 33 | 59 | 11 | $5,160 |
| Olanzapine Generic | 32 | 32 | 12 | $465 |
| Tamoxifen Citrate Generic | 25 | 51 | Under 11 | $743 |
| Tramadol Hcl Generic | 23 | 31 | Under 11 | $235 |
| Tasigna Nilotinib Hcl | 21 | 21 | Under 11 | $396K |
| Lynparza Olaparib | 19 | 19 | Under 11 | $258K |
Brand drugs: - claims; generic drugs: 1,143 claims; opioid claims: 69.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ines J Sanchez-Rivera $7,299 ($7,299 in general payments such as food, travel and fees) from 14 companies. The largest payer was Stemline Therapeutics Inc. with $5,483.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.